{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:47:18Z","timestamp":1782470838284,"version":"3.54.5"},"reference-count":26,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004925","name":"Texas Health and Human Services Commission","doi-asserted-by":"publisher","award":["1H79TI087739"],"award-info":[{"award-number":["1H79TI087739"]}],"id":[{"id":"10.13039\/100004925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Texas Targeted Opioid Response"},{"DOI":"10.13039\/100000058","name":"substance abuse and mental health services administration","doi-asserted-by":"publisher","award":["1H79TI087739"],"award-info":[{"award-number":["1H79TI087739"]}],"id":[{"id":"10.13039\/100000058","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Use &amp; Addiction Journal"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Patients with opioid use disorder need prompt buprenorphine\/naloxone (BUP\/NX) and naloxone nasal spray (NNS) access from pharmacies, but audit studies report substantial availability deficits. No specific intervention has increased BUP\/NX stocking, and little is known about the impact of transitioning specific NNS formulations to over-the-counter. The purpose of this study was to assess the impact of mailed academic detailing on BUP\/NX availability and the ability to obtain NNS without a prescription.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A prospective interventional study was conducted in a sample of 1000 Texas community pharmacies assigned 1:1 to intervention and control groups. The intervention group received academic detailing handouts with links to continuing education addressing BUP\/NX and NNS. Pre- and post-intervention audits were conducted using a telephonic secret-shopper approach. Outcomes for BUP\/NX included stocking, willingness to order if not stocked, and a composite outcome of stocking and willingness to order. NNS outcomes included availability without a prescription. McNemar and Wilcoxon signed-rank tests, and generalized estimating equations (GEE) were used for analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Data from 757 pharmacies were included in analyses (374 intervention, 383 control). Baseline BUP\/NX stocking was low (36.7%) with no statistically significant pre-to-post changes for either group. Most pharmacies were willing to order (60.5%) with no significant pre-to-post changes for either group. GEE analysis found no significant difference in odds of stocking between groups (aOR\u2009=\u20091.08,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.73), but the intervention group had a significantly higher likelihood to order (aOR\u2009=\u20092.25,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.02) and of achieving the composite outcome (aOR\u2009=\u20092.17,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.01). NNS availability increased in both groups but did not differ significantly between groups (aOR\u2009=\u20091.00,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.99).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>A mailed academic detailing intervention did not change NNS availability or BUP\/NX stocking but did modestly increase willingness to order BUP\/NX. This intervention is easily replicable and scalable, but modifications to increase the magnitude of its effect are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/29767342261422061","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T16:37:12Z","timestamp":1773765432000},"page":"762-771","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Increasing Buprenorphine and Naloxone Access in Texas Community Pharmacies Through an Academic Detailing Intervention"],"prefix":"10.1177","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3888-3457","authenticated-orcid":false,"given":"Sorina B.","family":"Torrez","sequence":"first","affiliation":[{"name":"The University of Texas at Austin, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0913-7145","authenticated-orcid":false,"given":"Kirk E.","family":"Evoy","sequence":"additional","affiliation":[{"name":"The University of Texas at Austin, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8880-4879","authenticated-orcid":false,"given":"Kelly R.","family":"Reveles","sequence":"additional","affiliation":[{"name":"The University of Texas at Austin, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5958-0159","authenticated-orcid":false,"given":"Lucas G.","family":"Hill","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Pharmacy, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth A.","family":"Lawson","sequence":"additional","affiliation":[{"name":"The University of Texas at Austin, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7969-5209","authenticated-orcid":false,"given":"Lindsey J.","family":"Loera","sequence":"additional","affiliation":[{"name":"The University of Texas at Austin, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.01.010"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/JAN.0000000000000230"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.15314"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2022.07.008"},{"key":"e_1_3_3_6_2","unstructured":"FDA approves first over-the-counter naloxone nasal spray. U.S. Food and Drug Administration. Updated March 29 2023. Accessed April 1 2024. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-over-counter-naloxone-nasal-spray"},{"key":"e_1_3_3_7_2","unstructured":"Engineering National Academies of Sciences and Medicine. Medications for Opioid Use Disorder Saves Lives. The National Academies Press; 2019. Accessed April 1 2024. https:\/\/nap.nationalacademies.org\/catalog\/25310\/medications-for-opioid-use-disorder-save-lives"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.7326\/M17-3107"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109518"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2023.04.029"},{"issue":"1","key":"e_1_3_3_11_2","first-page":"42","article-title":"Key features of academic detailing: development of an expert consensus using the delphi method","volume":"9","author":"Yeh JS","year":"2016","unstructured":"Yeh JS, VanHoof TJ, Fischer MA. Key features of academic detailing: development of an expert consensus using the delphi method. Am Health Drug Benefits. 2016;9(1):42-50.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2019.09.007"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2021.09.012"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.15892"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.208971"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109492"},{"key":"e_1_3_3_17_2","unstructured":"DEA announces important change to registration requirement. Drug Enforcement Agency. Updated January 12 2023. Accessed April 9 2024. https:\/\/deadiversion.usdoj.gov\/pubs\/docs\/A-23-0020-Dear-Registrant-Letter-Signed.pdf"},{"key":"e_1_3_3_18_2","unstructured":"Waiver elimination (MAT Act). Substance Abuse and Mental Health Services Administration. Updated October 10 2023. Accessed April 9 2024. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/waiver-elimination-mat-act"},{"key":"e_1_3_3_19_2","unstructured":"Drug Enforcement Agency. 88 FR 69879: Second temporary extension of COVID-19 telemedicine flexibilities for prescription of controlled medications. Fed Regist. 2023;88(194):69879-69883. Accessed April 1 2024. https:\/\/www.federalregister.gov\/d\/2023-22406"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103786"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001284"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2208055"},{"key":"e_1_3_3_23_2","unstructured":"Letter to Registrants. Drug Enforcement Administration. Updated March 8 2024 Accessed May 30 2025. deadiversion.usdoj. gov\/pubs\/docs\/Dear_Registrant_MOUD.pdf"},{"key":"e_1_3_3_24_2","unstructured":"Emergent BioSolutions\u2019 NARCAN\u00ae nasal spray launches over the counter making it possible for everyone to help save a life from an opioid overdose emergency. Emergent Biosolutions. Updated August 30 2023. Accessed April 9 2024. https:\/\/investors.emergentbiosolutions.com\/node\/22286\/pdf"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102701"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2022.08.017"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001244"}],"container-title":["Substance Use &amp; Addiction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342261422061","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/29767342261422061","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342261422061","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T09:51:41Z","timestamp":1782467501000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/29767342261422061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/29767342261422061"],"URL":"https:\/\/doi.org\/10.1177\/29767342261422061","relation":{},"ISSN":["2976-7342","2976-7350"],"issn-type":[{"value":"2976-7342","type":"print"},{"value":"2976-7350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]}}}